NEW
HAVEN, Conn., May 25, 2023
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of life-changing therapies for
people with debilitating diseases, including ultra-rare disorders,
will provide an overview of its platforms and pipeline at an
in-person Research and Development (R&D) Day taking place on
May 31 in New Haven, CT, concurrently with the Yale
Ventures Innovation Summit 2023. Members of Biohaven's senior
management team and key opinion leaders will be meeting with
investors and research analysts. Topics for discussion include:
- Bispecific Platform with potential application in
autoimmune and neurologic diseases
- Brain-penetrant TYK2/JAK1 inhibition for immune-mediated
brain disorders
- TRPM3 ion channel inhibition for neuropathic pain
- Kv7 ion channel activation for epilepsy, mood disorders,
and pain disorders
- Myostatin inhibition for neuromuscular and metabolic
diseases
- Glutamate modulation for OCD and rare diseases including
spinocerebellar ataxia
The R&D Day presentations will be made available following
the conclusion of the presentations on the Corporate Presentation
page of our company website. Investors interested in attending
the R&D update in-person should contact Jennifer Porcelli at Biohaven Investor Relations
as space is limited.
About Biohaven
Biohaven is a global
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of life-changing therapies for
people with debilitating diseases, including rare
disorders. Biohaven's experienced management team brings
with it a track record of delivering new drug approvals for
products for diseases such as migraine, depression, bipolar
disorder and schizophrenia. The company is advancing a pipeline of
therapies for diseases with little or no treatment options,
leveraging its proven drug development capabilities and proprietary
platforms, including Kv7 ion channel modulation for epilepsy and
neuronal hyperexcitability, glutamate modulation for
obsessive-compulsive disorder and spinocerebellar ataxia, myostatin
inhibition for neuromuscular diseases, and brain-penetrant
TYK2/JAK1 inhibition for immune-mediated brain
disorders. Biohaven's portfolio of early- and late-stage
product candidates also includes discovery research programs
focused on TRPM3 channel activation for neuropathic pain, CD-38
antibody recruiting, bispecific molecules for multiple myeloma,
antibody drug conjugates (ADCs), and targeted extracellular protein
degrader platform technology (MoDE™) with potential application in
neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The use of certain words,
including "continue", "plan", "will", "believe", "may", "expect",
"anticipate" and similar expressions, is intended to identify
forward-looking statements. Investors are cautioned that any
forward-looking statements, including statements regarding the
future development, timing and potential marketing approval and
commercialization of development candidates are not guarantees of
future performance or results and involve substantial risks and
uncertainties. Actual results, developments and events may differ
materially from those in the forward-looking statements as a result
of various factors including: the expected timing, commencement and
outcomes of Biohaven's planned and ongoing clinical trials; the
timing of planned interactions and filings with the Food and Drug
Administration; the timing and outcome of expected regulatory
filings; complying with applicable U.S. regulatory requirements;
the potential commercialization of Biohaven's product candidates;
the potential for Biohaven's product candidates to be first in
class therapies; and the effectiveness and safety of Biohaven's
product candidates. Additional important factors to be considered
in connection with forward-looking statements are described in
Biohaven's filings with the Securities and Exchange Commission,
including within the sections titled "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations". The forward-looking statements are made as
of the date of this new release, and Biohaven does not undertake
any obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as
required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-rd-day-at-yale-school-of-management-301835154.html
SOURCE Biohaven Ltd.